

Published in final edited form as:

J Rheumatol. 2020 March ; 47(3): 441–448. doi:10.3899/jrheum.180574.

Effect of timing and duration of statin exposure on risk of hip or knee revision arthroplasty: a population-based cohort study

Michael J Cook*,

Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

Antony K Sorial*,

Institute of Genetic Medicine, Newcastle University, UK

Mark Lunt,

Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

Tim N Board#,

The Centre for Hip Surgery, Wrightington Hospital, Wrightington Wigan and Leigh NHS Foundation Trust, Wigan UK

Terence W O'Neill#

Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; Department of Rheumatology, Salford Royal NHS Foundation Trust, Salford, UK

Abstract

Address correspondence to: Professor Terence O'Neill, Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal and Dermatological Sciences, Stopford Building, The University of Manchester, Oxford Road, Manchester, M13 9PT, United Kingdom, Tel: + 44 (0) 1612751647, Fax: + 44 (0) 1613060547, terence.o'neill@manchester.ac.uk.

*Michael J Cook and Antony K Sorial contributed equally to this manuscript

#Terence W O'Neill and Tim N Board are joint senior authors

All authors declare that they have no conflicts of interest

M J Cook (<https://orcid.org/0000-0002-6551-9722>), MSc, Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal & Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

A K Sorial (<https://orcid.org/0000-0002-4449-014X>), MRCS, Institute of Genetic Medicine, Newcastle University, UK

M Lunt (<https://orcid.org/0000-0002-2391-5575>), PhD, Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal & Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom

T N Board (<https://orcid.org/0000-0002-3295-2087>), MD, The Centre for Hip Surgery, Wrightington Hospital, Wrightington Wigan and Leigh NHS Foundation Trust, Wigan UK

T W O'Neill (<https://orcid.org/0000-0002-8896-4677>), MD, Arthritis Research UK Centre for Epidemiology, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK & NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, UK & Department of Rheumatology, Salford Royal NHS Foundation Trust, Salford, UK

Objectives—To determine whether the timing and also duration of statin exposure following total hip/knee arthroplasty (THA/TKA) influences the risk of revision arthroplasty.

Methods—Subjects from the Clinical Practice Research Datalink, a large population-based clinical database, who had THA/TKA from 1988-2016 were included. Propensity score adjusted Cox regression models were used to determine the association between statin exposure and the risk of revision THA/TKA, i) at any time and ii) if first exposed 0-1, 1-5, or >5 years following THA/TKA. We also investigated the effect of duration of statin exposure (<1, 1-2, 2-3, 3-4, 4-5, >5 years).

Results—151,305 participants were included. 65,032 (43%) were exposed to statins during follow up and 3,500 (2.3%) had revision arthroplasty. In a propensity score adjusted model, exposure to statins was associated with a reduced risk of revision arthroplasty (HR (95% CI) 0.82 (0.75, 0.90)). Participants first exposed within 1 year and between 1 and 5 years following THA/TKA (vs unexposed) had a reduced risk of revision arthroplasty (HR (95% CI) 0.82 (0.74, 0.91) and 0.76 (0.65, 0.90), respectively). In relation to duration of statin therapy, participants exposed for more than 5 years in total (vs <1 year) had a reduced risk of revision (HR (95% CI) 0.74 (0.62, 0.88)).

Conclusion—Statin therapy initiated up to 5 years following THA/TKA may reduce the risk of revision arthroplasty.

Key Indexing Terms

Arthroplasty; Hip Replacement; Knee Replacement; Osteoarthritis; Epidemiology

Introduction

Osteoarthritis is a chronic, painful and disabling condition associated with significant and increasing economic cost in the UK and globally (1). Total joint replacement is the definitive treatment for moderate to severe osteoarthritis of the hip and knee in those who have not responded to medical therapy. The number of total hip/knee arthroplasty (THA/TKA) procedures carried out in the UK is increasing and is predicted to increase further, in part due to demographic changes (2). The cumulative 5-year probability for revision of primary THA and TKA in the UK is around 2.5% (3). Revision surgery is more complex, more costly, and has poorer clinical outcomes than primary joint replacement (4). Therefore, any factors which may help reduce revision rates would help reduce long term morbidity linked with joint replacement surgery.

There is experimental evidence that statins may have a beneficial effect on bone homeostasis by modulating inflammatory cytokine responses, promoting osteoblast directed bone formation and reducing osteoclastic bone resorption (5–7). Animal studies have shown that local and systemic administration of statins following implantation of prosthesis improves osseointegration and increases the mechanical strength of the bone-implant interface within 6 weeks of prosthesis implantation (7–11). Periprosthetic osteolysis, degradation of bone around the implant and inhibition of bone formation, leading to aseptic loosening of the implant, is the overall most common indication for revision surgery (12), while instability and infection are common indications for revisions occurring within 5 years of the primary

joint replacement (13, 14). An inflammatory response to implant wear-related debris around the joint is the major initiating event in the development of periprosthetic osteolysis (15). There is some evidence that statins may inhibit this inflammatory reaction by attenuating the production of pro-inflammatory cytokines (16), and may therefore potentially reduce subsequent periprosthetic osteolysis (17).

Two observational studies have suggested that exposure to statins may be associated with a reduced risk of revision of primary arthroplasty (18, 19). A study from Denmark showed that postoperative statin use was associated with an all-cause adjusted relative risk (95% CI) of revision surgery following total hip arthroplasty of 0.34 (0.28, 0.41) (18). However, this study did not take into account time-varying statin exposure, which is likely to have resulted in an over estimation of the effect of statin exposure on the risk of revision. A second study, using data from the Clinical Practice Research Datalink (CPRD) and the Danish National Health System, used a number of approaches including a time-dependent model with follow up time divided into two periods defining exposed and unexposed periods; from the time of primary joint surgery until a day before the first postoperative statin prescription (non-exposed), and from the date of the first prescription until the end of follow up (exposed). Using this approach statin exposure was associated with a more modest reduced risk of revision (incidence rate ratio (95%CI), 0.90 (0.85, 0.96)) (19). These previous observational studies, however, did not consider whether the timing of first statin exposure relative to the primary surgery was significant in influencing the risk of revision. This may be important, since experimental studies, as outlined above, suggest different mechanisms of action which are dependent on the timing of the exposure relative to the primary surgery. If for example the effect was to enhance osseointegration, then it is likely that the effect would be observed only in those who received statins in the early post-operative period.

The primary aim of this study was to determine whether the timing of statin exposure influences the risk of revision surgery in patients who have undergone a primary THA/TKA. We also looked at whether duration of therapy impacted on the risk of revision.

Materials and Methods

Study population and setting

The Clinical Practice Research Datalink (CPRD) is a database of anonymised primary care records of over 11.3 million patients (~6.9% of the UK population), and is broadly representative of the UK general population (20). The CPRD includes demographic details, medication prescriptions, diagnoses, referrals, and hospital admissions with their major outcomes. The CPRD was used to retrospectively identify patients who had undergone a primary THA or TKA in the period 1 January 1988 to 31 December 2016 for inclusion in this study. Patients who were aged <40 years, had a history of hip fracture, or who had inflammatory arthritis at the time of primary THA/TKA, were excluded from the analyses. Surgical procedures are recorded in CPRD using Read/OXMIS codes. A list of codes used to identify those with primary THA/TKA, based on a previously published list (21), is shown in Supplementary Table 2.

Ascertainment of outcome

The primary outcome of this study was all-cause revision arthroplasty. A list of Read/OXMIS codes used to identify patients in CPRD who had a revision arthroplasty (22), is given in Supplementary Table 3.

Primary exposure

The primary exposure was statin use from the time of primary arthroplasty, identified using prescription records in the CPRD. In the primary analyses, participants were modelled as continuously exposed from the date of their first statin prescription during follow up. Participants were classified as unexposed at a given time if they had not been exposed to statins from the date of their primary THR/TKR up to that time. In a sensitivity analysis, adjustment was made for exposure to statins in the 12 months leading up to the study start date.

Covariates

Following a review of the literature to identify potential confounders, the year of primary THA/TKA, age, sex, body mass index (BMI), smoking status (never, former, current), alcohol intake (non-drinker, current drinker, ex-drinker), General Practice deprivation score (defined by the Index of Multiple Deprivation), joint replaced (hip or knee), and selected morbidities were included as covariates in the analyses (see supplementary file). Morbidities were identified using Read/OXMIS codes recorded in CPRD.

Statistical analyses

Baseline characteristics for participants exposed/unexposed to statins during the study period were compared using unpaired, two-tailed t-tests for continuous variables and chi-square tests for categorical variables. Cox regression models were used to estimate the hazard of revision in participants exposed to statins compared to those unexposed to statins during follow up. In all Cox models, the index date was the date of the primary THA/TKA. Participants were censored at the date of revision surgery, the date at which their GP practice stopped contributing data to the CPRD, the date the participant transferred out of their GP surgery, the date of death, or 31 December 2016 (whichever came first). Participants who had more than one primary THA/TKA were censored at the date of their second THA/TKA, since the side of the primary THA/TKA is not recorded in the CPRD and therefore it was not possible to determine which primary surgery the revision related to. Therefore, inferences about, and comparisons of, the hazard of revision at any time relate to participants who were still alive at that time.

We undertook analysis of the whole cohort and separately assessed hip and knee arthroplasties. Multiple imputation by chained equations was used to impute missing values of BMI, smoking, and alcohol intake. All covariates included in the fully adjusted model were used in the imputation model, with 10 iterations. Propensity score adjustment was used, however, as the primary method to control for potential confounding by indication (23). Separate logistic regression models were used to determine the propensity score for first exposure to statins in each of the following time periods: 0-1 years, 1-5 years, >5 years following primary THA/TKA. The log odds of the propensity score was included in the Cox

models, as the propensity score was not normally distributed. To test whether the association between the log odds of the propensity score and survival was linear, quintiles of the log odds of the propensity score were plotted against log failure rate.

A categorical, time-varying variable was created to indicate the timing of first statin exposure. The time-varying variable had four categories; unexposed, and first exposed 0-1 years, 1-5 years, >5 years following the primary THA/TKA. Each participant exposed to statins was classified as exposed in the relevant period from the date of their first statin exposure. Each exposed participant appeared in only one of the timing categories, determined by the timing of first exposure. The categorical timing variable was entered into a Cox regression model. The referent group comprised participants who were not exposed to statins during follow up.

To determine the association between duration of statin exposure and revision risk, the cumulative number of days exposed was calculated for each participant at all failure times (revision dates) in the cohort. The cumulative days exposed was categorised as: <1 year (365 days) (referent), 1-2 years, 2-3 years, 3-4 years, 4-5 years, and >5 years and included as a covariate in a fully adjusted Cox model.

In order to estimate how robust any observed association between statin exposure and revision risk is to unmeasured or residual confounding, a recently introduced measure, the E-value, was calculated (24). The E-value is defined as the minimum strength of association, on the risk ratio scale, that an unmeasured confounder would need to have with both statin exposure and revision risk to fully explain away any observed effect estimate (24). All statistical analyses were carried out using STATA version 13 (StataCorp, College Station, TX, USA).

Ethics approval was obtained from the Independent Scientific Advisory Committee for the Medicines and Healthcare Products Regulatory Agency (reference 16_201R).

Results

Subjects

Of the 164,224 people who had a THA/TKA from January 1988 to December 2016, 12,919 were excluded who had a history of hip fracture, were <40 years old, or had inflammatory arthritis at the time of primary THA/TKA, leaving 151,305 participants who were included in the analysis (Figure 1). Of those included in the analyses, 78,594 had a THA and 72,711 had a TKA (Figure 1). The 14th Annual National Joint Registry (NJR) Report included 1,866,420 THA/TKA for the period 1 April 2003 – 31 December 2016 (3). The number of participants included in our study who had a THA/TKA in the same period was 116,716, though since there are differences in the geographical areas covered by the NJR and the CPRD during the study period, a direct comparison is not possible. 65,032 (43% of the study cohort) were exposed to statins during the follow up period and 3,500 participants (2.3% of the study cohort) had revision arthroplasty. The median (inter-quartile range (IQR)) follow up time was 3.9 (1.1, 7.8) years. The mean (standard deviation) age of the study cohort was 69.7 (9.9) years and 59% of the study participants were female.

Baseline Characteristics: Statin and non-Statin users

Compared to those who were not exposed to statins at baseline, those who were exposed to statins were slightly older (70.7 yrs vs 69.1 yrs), less likely to be female (53.4% vs 62.4%), had a higher BMI (29.6 kg/m² vs 28.6 kg/m²), less likely to have never smoked (45.5% vs 55.7%), less likely to have never consumed alcohol (45.5% vs 55.7%), were more likely to be an ex-drinker (44.3% vs 33.1%), were more likely to have most of the comorbidities considered and use most of the medications considered (Table 1). Baseline characteristics for participants who did/did not have revision arthroplasty are shown in supplementary table 1.

Influence of timing of first statin therapy on THA / TKA revision rates

Of those exposed to statins during follow up, 852 (1.3%) had revision arthroplasty, compared to 2,648 (3.1%) of those not exposed to statins. During the follow up period, in the propensity score adjusted model, compared to those who were not exposed to statins, those who were exposed had a reduced hazard ratio for revision surgery (hip or knee) (HR (95% CI), 0.82 (0.75, 0.90)). Stratified by joint, statin therapy was associated with a reduced hazard ratio for hip (HR (95%CI) 0.86 (0.76, 0.98)) and knee (HR (95%CI) 0.76 (0.66, 0.88)) revision surgery. We did not have information on the type of implants used. Metal-on-metal hip implants are linked with a higher risk of revision. We carried out a sensitivity analysis restricted to THAs carried out before 2000 and after 2009, when metal-on-metal bearing surfaces were not commonly used. We found statin exposure to be associated with a reduced hazard ratio for revision (HR (95%CI) 0.83 (0.68, 1.00)), with an effect size was similar to the HR as that observed when including all subjects

Exposure in the first 5 years following surgery appeared protective; compared to those who were not exposed to statins, the hazard ratio (95%CI) of revision in those first exposed to statins in the periods 0-1, 1-5, and >5 years after the primary surgery was 0.82 (0.74, 0.91), 0.76 (0.65, 0.90), and 0.95 (0.76, 1.19), respectively though the confidence intervals for the > 5 year category included unity (Table 2). In separate analyses looking at the individual joint sites, the results were similar for those who had had a knee arthroplasty with first exposure in the periods 0-1 and 1-5 years following surgery associated with reduced revision risk in the propensity score adjusted model (HR (95%CI) 0.76 (0.65, 0.89) and 0.71 (0.54, 0.92), respectively (Table 2). For hips, only first exposure in the period 1-5 years following THA was associated with a statistically significant reduced risk of revision (HR (95%CI) 0.80 (0.65, 0.99)) (Table 2). Visual inspection of a plot of quintiles of the log odds of the propensity score and log failure rate for each propensity score model confirmed a linear association.

Propensity score adjustment was used in the primary analysis. Multivariable, fully adjusted models gave similar effect sizes to the propensity score adjusted models, though the confidence intervals around the revision risks in the whole cohort (HR (95%CI) 0.86 (0.73, 1.03)) and also hips (HR (95%CI) 0.87 (0.68, 1.10)) included unity.

Influence of duration of statin therapy on THA / TKA revision rates

Compared to participants exposed to statins for a total duration of less than one year (reference), those exposed for more than a total of 5 years had a reduced risk of revision, (HR (95% CI) 0.74 (0.62, 0.88)), (Figure 2).

Sensitivity analyses

In total, 39,462 participants were exposed to statins in the year leading up to the study start. Results from sensitivity analyses adjusting for statin exposure in the year leading up to the study start were not significantly different from the main analyses (data not shown). We looked also at those who had contributed data to CPRD from January 1988 for at least 10 years and who had no primary THA/TKA during that time. Among this smaller subset, during the observation period from 1998 to 2016, the hazard ratio (95% CI) for revision among those exposed to statins compared to those unexposed was as in the main analysis protective though the confidence bounds included unity, HR (95% CI), 0.88 (0.73,1.05).

The E-value (lower 95% CI) for the hazard ratio for revision in participants first exposed to statins in the period 0-1 and 1-5 years after THA/TKA, compared to those who were unexposed, in the fully adjusted model was 1.49 (1.37) and 1.64 (1.37), respectively. The E-value represents the necessary minimum strength of association that an unmeasured confounder would need to have with both the exposure and the outcome in order to explain away the observed association between postoperative statin exposure and revision risk (24).

Discussion

In this analysis of a large, population-based cohort, statin therapy was linked with a reduced risk of revision hip and knee surgery. Timing of first exposure to statin therapy appeared to influence the risk of revision surgery with first exposure within 5 years of surgery being linked with a reduction in risk. There was some evidence that duration of therapy may also be important; compared to those who took therapy for less than a year those who were on statin therapy for more than 5 years had a reduced risk of revision surgery.

Our results are consistent with two previous studies suggesting a protective effect of statin therapy on risk of revision surgery. Thillemann (2010), in an analysis of 57,581 THA recorded in the Danish Hip Arthroplasty Register from 1996 to 2005, suggested that postoperative statin use was associated with an adjusted relative risk of revision (95% CI) of 0.34 (0.28, 0.41) (18). Meanwhile Lalmohamed (2016), using data from the CPRD and the Danish National Health System (DNHS), with a combined 189,286 THA/TKA recorded from 1998 to 2007, suggested that, with statin exposure defined in a time-dependent manner, postoperative statin exposure was associated with an adjusted incidence rate ratio (95% CI) of 0.90 (0.85, 0.96) (19). Differences in study design, duration of follow up, and analytic approach may potentially explain the discrepancy in effect size between these two studies. Thillemann (2010) used a time-fixed exposure variable (any postoperative statin exposure) in logistic regression models, whilst Lalmohamed (2016) used Cox regression with time dependent statin exposure. However, to our knowledge, there are no data which have looked at the influence of timing of first exposure to statin therapy on the risk of revision.

Laboratory and animal studies have suggested that statins may influence biological processes occurring at different phases following arthroplasty; principally osseointegration, by promoting bone formation (7–10), and periprosthetic osteolysis, by attenuating the inflammatory response to implant wear-related debris (16). The fact that in our study statin therapy given more than 1 year following the original surgery was linked with a reduced risk of subsequent revision would suggest that the mechanism by which statins may confer protection is not simply related to an effect on osseointegration, which would typically be complete within 6 months of surgery. Other mechanisms are likely to be involved including perhaps an effect on loosening (periprosthetic osteolysis) of the implants; our finding that a longer duration of exposure appeared to be protective would be in keeping with this also. A small proportion of revisions are due to the occurrence of periprosthetic fractures and it is possible that statin therapy may reduce these events. However, as we did not have information about the indications for revision surgery we cannot make further comment on this.

Given the increasing number of THA/TKA carried out globally and the increased costs and poorer clinical outcomes associated with revision surgery (4), if the results of our study are confirmed, statins may potentially provide an approach to reducing the risk of revision surgery in patients undergoing primary THA/TKA. However, further research is required to confirm the findings and identify potential mechanism by which statins are linked with a reduced risk. Although statin therapy is effective and safe in the context of cardiovascular disease prevention, statin therapy is not without potential risks, which should also be considered (25).

Strengths of our study include a large, representative sample of UK patients with detailed longitudinal prescription data from primary care records, as well as detailed demographic and morbidity data (20). The results should be interpreted with reference to potential limitations, including, as with all observational studies, the potential that unmeasured or residual confounding may have influenced our results. However, a review of the literature was carried out to identify putative confounders, which were accounted for in propensity score adjusted analysis (23). Furthermore, sensitivity analyses showed that any unmeasured confounding would need to be substantial in order to explain away the observed associations. Improvements in surgical techniques have reduced revision rates during the study period (1988-2016). However, the general decrease in revision rates over time is not likely to have influenced the relationship between statin exposure and revision risk, since improvements in surgical techniques are unrelated to statin use. Data was not available in CPRD about which joint (left/right) each primary THA/TKA relates to. It was therefore necessary to censor participants with bilateral THA/TKA, at the time of the second primary operation, since any subsequent revision could not be accurately linked to the correct primary. The effect of this, however, would be to tend to reduce the likelihood of finding a significant association between statin therapy and risk of revision. We cannot exclude misclassification due to the occurrence of joint replacement surgery prior to a subject contributing data to the CPRD who subsequently had a second joint replacement surgery on the contralateral side and then a revision. The observed revision rate in our study (2.3%) was, however, broadly similar to that reported by the National Joint Registry (2.4% in the first 5 years following primary hip replacement and 2.6% in the first 5 years following total

knee replacement) (3). Other factors which may influence revision rates, such as for example implant design and fixation type, were not available in the CPRD.

In summary in this analysis of data from the CPRD, statin therapy was linked with a reduced risk of revision hip and knee surgery. Timing of first exposure to statin therapy appeared to influence the risk of revision surgery with first exposure within 5 years of surgery being linked with a reduction in risk. The mechanism by which statin therapy is linked with a reduced risk of revision surgery is unknown, though does not appear to be related solely to an effect on osseointegration of the primary prosthesis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This study is based on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. The data is provided by patients and collected by the NHS as part of their care and support. The interpretation and conclusions contained in this study are those of the authors alone. Dr Antony K Sorial was funded through The National Institute for Health Research Integrated Academic Training programme.

This study was supported by the John Charnley Trust, the Three Wishes Foundation, the Endocrine Research Fund, Salford Royal NHS Foundation Trust, and Arthritis Research UK (grant number 21755). Dr Antony K Sorial was funded through The National Institute for Health Research Integrated Academic Training programme.

References

1. Chen A, Gupte C, Akhtar K, Smith P, Cobb J. The global economic cost of osteoarthritis: How the uk compares. *Arthritis*. 2012; 2012
2. Culliford D, Maskell J, Judge A, Cooper C, Prieto-Alhambra D, Arden NK, et al. Future projections of total hip and knee arthroplasty in the uk: Results from the uk clinical practice research datalink. *Osteoarthritis and cartilage*. 2015; 23:594–600. [PubMed: 25579802]
3. The Editorial Board. [Accessed 8 October 2018] National joint registry 14th annual report. 2017. <http://www.njrreports.org.uk/Portals/0/PDFdownloads/NJR%2014th%20Annual%20Report%202017.pdf>
4. Bozic KJ, Kurtz SM, Lau E, Ong K, Vail TP, Berry DJ. The epidemiology of revision total hip arthroplasty in the united states. *The Journal of bone and joint surgery American volume*. 2009; 91:128–33. [PubMed: 19122087]
5. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. *Science*. 1999; 286:1946–9. [PubMed: 10583956]
6. von Knoch F, Heckelei A, Wedemeyer C, Saxler G, Hilken G, Henschke F, et al. The effect of simvastatin on polyethylene particle-induced osteolysis. *Biomaterials*. 2005; 26:3549–55. [PubMed: 15621245]
7. Ayukawa Y, Okamura A, Koyano K. Simvastatin promotes osteogenesis around titanium implants. *Clin Oral Implants Res*. 2004; 15:346–50. [PubMed: 15142098]
8. Basarir K, Erdemli B, Can A, Erdemli E, Zeyrek T. Osseointegration in arthroplasty: Can simvastatin promote bone response to implants? *International orthopaedics*. 2009; 33:855–9. [PubMed: 18157535]
9. Du Z, Chen J, Yan F, Xiao Y. Effects of simvastatin on bone healing around titanium implants in osteoporotic rats. *Clin Oral Implants Res*. 2009; 20:145–50. [PubMed: 19077150]
10. Yin H, Li JM, Yu XC, Fu ZH. Effects of simvastatin on osseointegration in a canine total hip arthroplasty model: An experimental study. *J Arthroplasty*. 2011; 26:1534–9. [PubMed: 21256697]

11. Moriyama Y, Ayukawa Y, Ogino Y, Atsuta I, Koyano K. Topical application of statin affects bone healing around implants. *Clin Oral Implants Res.* 2008; 19:600–5. [PubMed: 18422989]
12. Gallo J, Goodman SB, Kontinen YT, Raska M. Particle disease: Biologic mechanisms of periprosthetic osteolysis in total hip arthroplasty. *Innate immunity.* 2013; 19:213–24. [PubMed: 22751380]
13. Ulrich SD, Seyler TM, Bennett D, Delanois RE, Saleh KJ, Thongtrangan I, et al. Total hip arthroplasties: What are the reasons for revision? *International orthopaedics.* 2008; 32:597–604. [PubMed: 17443324]
14. Sharkey PF, Lichstein PM, Shen C, Tokarski AT, Parvizi J. Why are total knee arthroplasties failing today--has anything changed after 10 years? *J Arthroplasty.* 2014; 29:1774–8. [PubMed: 25007726]
15. Purdue PE, Koulouvaris P, Potter HG, Nestor BJ, Sculco TP. The cellular and molecular biology of periprosthetic osteolysis. *orthopaedics and related research.* 2007; 454:251–61.
16. Laing AJ, Dillon JP, Mulhall KJ, Wang JH, McGuinness AJ, Redmond PH. Statins attenuate polymethylmethacrylate-mediated monocyte activation. *Acta orthopaedica.* 2008; 79:134–40. [PubMed: 18283585]
17. Lubbeke A, Garavaglia G, Rothman KJ, Bonvin A, Roussos C, Miozzari H, et al. Statins may reduce femoral osteolysis in patients with total hip arthroplasty. *J Orthop Res.* 2013; 31:814–20. [PubMed: 23138498]
18. Thillemann TM, Pedersen AB, Mehnert F, Johnsen SP, Soballe K. The risk of revision after primary total hip arthroplasty among statin users: A nationwide population-based nested case-control study. *The Journal of bone and joint surgery American volume.* 2010; 92:1063–72. [PubMed: 20439650]
19. Lalmohamed A, van Staa TP, Vestergaard P, Leufkens HG, de Boer A, Emans P, et al. Statins and risk of lower limb revision surgery: The influence of differences in study design using electronic health records from the united kingdom and denmark. *American journal of epidemiology.* 2016; 184:58–66. [PubMed: 27317693]
20. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data resource profile: Clinical practice research datalink (cprd). *International journal of epidemiology.* 2015; 44:827–36. [PubMed: 26050254]
21. Prieto-Alhambra D, Javaid MK, Judge A, Maskell J, Cooper C, Arden NK, et al. Hormone replacement therapy and mid-term implant survival following knee or hip arthroplasty for osteoarthritis: A population-based cohort study. *Annals of the rheumatic diseases.* 2015; 74:557–63. [PubMed: 24451241]
22. Prieto-Alhambra D, Javaid MK, Judge A, Murray D, Carr A, Cooper C, et al. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: Population based retrospective cohort study. *Bmj.* 2011; 343:d7222. [PubMed: 22147909]
23. Normand SL, Sykora K, Li P, Mamdani M, Rochon PA, Anderson GM. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. *Bmj.* 2005; 330:1021–3. [PubMed: 15860831]
24. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: Introducing the e-value. *Annals of internal medicine.* 2017; 167:268–74. [PubMed: 28693043]
25. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet.* 2016; 388:2532–2561. [PubMed: 27616593]




Figure 1. Population flow diagram

THA: Total hip arthroplasty, TKA: Total knee arthroplasty, RA: Rheumatoid arthritis

*The study period is the time from primary THA/TKA until revision or censoring




Figure 2. Risk of revision by duration of exposure

Association between total duration of postoperative statin exposure and risk of revision. Exposed for less than one year is the referent group. Results from a fully adjusted Cox regression model

Table 1
Participant characteristics at baseline

	Statin users (n=65,032)	Statin non-users (n=86,273)	<i>p</i> ¹
	Mean (SD) or n (%)		
Age, years	70.3 (8.5)	69.2 (10.8)	<0.001
Female	34,942 (53.7%)	54,297 (62.9%)	<0.001
BMI (kg/m ²) ²	29.6 (2.4)	28.5 (5.6)	<0.001
Smoking status ³			
<i>Never</i>	28,748 (46.5%)	44,016 (55.7%)	
<i>Former</i>	26,448 (42.8%)	26,344 (33.3%)	<0.001
<i>Current</i>	6,601 (10.7%)	8,661 (11.0%)	
Alcohol intake ⁴			
<i>Non-drinker</i>	12,391 (19.8%)	14,657 (18.9%)	
<i>Current drinker</i>	48,394 (77.3%)	61,347 (79.0%)	<0.001
<i>Ex-drinker</i>	1,824 (2.9%)	1,631 (2.1%)	
Multiple index of deprivation, decile	5.6 (2.9)	5.5 (2.9)	<0.0001
Comorbid conditions (diagnosis of / history of)			
Osteoarthritis	44,577 (68.6%)	55,285 (64.1%)	<0.001
Asthma	7,830 (12.0%)	9,683 (11.2%)	<0.001
Malabsorptive syndromes	5,525 (8.5%)	6,568 (7.6%)	<0.001
Hypertension	37,336 (57.4%)	29,352 (34.0%)	<0.001
Hyperlipidaemia	15,389 (23.7%)	4,247 (4.9%)	<0.001
Ischaemic heart disease	13,411 (20.6%)	3,817 (4.4%)	<0.001
Stroke	5,207 (8.0%)	2,124 (2.5%)	<0.001
Myocardial infarction	5,590 (8.6%)	1,161 (1.4%)	<0.001
Congestive heart failure	1,984 (3.1%)	1,663 (1.9%)	<0.001
Malignancy	451 (0.7%)	631 (0.7%)	0.39
Chronic obstructive pulmonary disease	2,559 (3.9%)	2,539 (2.9%)	<0.001
Kidney failure	39 (0.06%)	22 (0.03%)	<0.001
Cerebrovascular disease	4,512 (6.9%)	2,123 (2.5%)	<0.001
Peripheral vascular disease	1,796 (2.8%)	756 (0.88%)	<0.001
Dementia	296 (0.46%)	458 (0.53%)	0.04
Neoplasm	5,336 (8.2%)	7,034 (8.2%)	0.72
Diabetes	10,957 (16.9%)	2,924 (3.4%)	<0.001
Ulcers	3,537 (5.4%)	3,568 (4.1%)	<0.001
Hemiplegia	134 (0.2%)	109 (0.1%)	<0.001
Renal disease	8,285 (12.7%)	6,032 (7.0%)	<0.001
Inflammatory bowel disease	86 (0.1%)	142 (0.2%)	0.11
Medication			
Proton pump inhibitors	30,594 (47.0%)	34,487 (40.0%)	<0.001
Antiarrhythmics	44,502 (68.4%)	40,828 (47.3%)	<0.001
Anticonvulsants	5,802 (8.9%)	6,665 (7.7%)	<0.001

	Statin users (n=65,032)	Statin non-users (n=86,273)	<i>p</i> ¹
	Mean (SD) or n (%)		
Antidepressants	19,226 (29.6%)	23,247 (27.0%)	<0.001
Anti-parkinson drugs	1,020 (1.6%)	1,410 (1.6%)	0.31
Thiazide diuretics	28,528 (43.9%)	25,205 (29.2%)	<0.001
Anxiolytics	1,273 (2.0%)	1,420 (1.7%)	<0.001
Platelet inhibitors	14,196 (21.8%)	7,435 (8.6%)	<0.001
Warfarin	4,765 (7.3%)	3,870 (4.5%)	<0.001
Angiotensin-converting enzyme inhibitors	13,607 (20.9%)	9,180 (10.6%)	<0.001
Beta blockers	29,026 (44.6%)	21,691 (25.1%)	<0.001
Calcium channel blockers	27,131 (41.7%)	19,300 (22.4%)	<0.001
Loop diuretics	13,748 (21.1%)	12,688 (14.7%)	<0.001
Nonstatin lipid lowering drugs	4,148 (6.4%)	1,962 (2.3%)	<0.001
Corticosteroids	26,203 (40.3%)	30,778 (35.7%)	<0.001
Oral antidiabetic drugs	1,691 (2.6%)	381 (0.44)	<0.001
Nonsteroidal anti-inflammatory drugs	55,429 (85.2)	71,298 (82.6%)	<0.001
Hormone replacement therapy	11,613 (17.9%)	16,488 (19.1%)	<0.001
Bisphosphonates	4,437 (6.8%)	5,942 (6.9%)	0.62
Calcium / vitamin D	6,746 (10.4%)	8,647 (10.0%)	0.03
Selective oestrogen receptor modulators	1,219 (1.9%)	2,067 (2.4%)	<0.001

SD: standard deviation, BMI: body mass index

¹ p-value from a t-test for continuous variables and a chi-square test for categorical variables

² Data on BMI available for 72,432 study participants

³ Data for smoking status available for 140,785 participants

⁴ Data on alcohol intake available for 140,244 participants

Table 2
Hazard ratio for revision by timing of exposure to statins following primary arthroplasty

Exposure	Hazard ratio (95% CI) for revision			
	Unadjusted	Adjusted for year of primary, age, and sex	Fully adjusted ¹	Propensity score adjusted ²
<i>Whole cohort</i>				
Unexposed	Referent	Referent	Referent	Referent
Any exposure	0.63 (0.58, 0.68)	0.81 (0.75, 0.88)	0.86 (0.73, 1.03)	0.82 (0.75, 0.90)
Unexposed	Referent	Referent	Referent	
0-1	0.59 (0.54, 0.64)	0.80 (0.73, 0.88)	0.82 (0.73, 0.92)	0.82 (0.74, 0.91)
1-5	0.69 (0.59, 0.81)	0.78 (0.66, 0.92)	0.78 (0.66, 0.92)	0.76 (0.65, 0.90)
>5	0.98 (0.78, 1.22)	0.94 (0.75, 1.18)	0.93 (0.74, 1.17)	0.95 (0.76, 1.19)
<i>Hips³</i>				
Unexposed	Referent	Referent	Referent	
Any exposure	0.66 (0.59, 0.73)	0.85 (0.77, 0.95)	0.87 (0.68, 1.10)	0.86 (0.76, 0.98)
Unexposed	Referent	Referent	Referent	
0-1	0.60 (0.53, 0.68)	0.84 (0.74, 0.96)	0.85 (0.73, 0.99)	0.87 (0.75, 1.01)
1-5	0.71 (0.58, 0.88)	0.82 (0.67, 1.02)	0.82 (0.66, 1.01)	0.80 (0.65, 0.99)
>5	0.97 (0.74, 1.26)	0.96 (0.74, 1.25)	0.95 (0.73, 1.24)	0.96 (0.73, 1.24)
<i>Knees⁴</i>				
Unexposed	Referent	Referent	Referent	
Any exposure	0.61 (0.54, 0.69)	0.77 (0.68, 0.87)	0.78 (0.68, 0.90)	0.76 (0.66, 0.88)
Unexposed	Referent	Referent	Referent	
0-1	0.59 (0.51, 0.67)	0.76 (0.67, 0.88)	0.79 (0.67, 0.93)	0.76 (0.65, 0.89)
1-5	0.67 (0.52, 0.87)	0.71 (0.55, 0.93)	0.72 (0.55, 0.94)	0.71 (0.54, 0.92)
>5	1.03 (0.67, 1.56)	0.93 (0.61, 1.42)	0.92 (0.60, 1.41)	0.98 (0.64, 1.49)

Risk of revision in those exposed to statins vs unexposed during follow up and by timing of first postoperative statin exposure. Timing of first postoperative statin exposure is measured in years since the primary surgery. Results from a Cox regression model.

¹ Adjusted for year of primary TJA, age, sex, body mass index (BMI), smoking status (never, former, current), alcohol intake (non-drinker, current drinker, ex-drinker), General Practice deprivation score (defined by the Index of Multiple Deprivation), joint replaced (hip or knee), diagnosis of osteoarthritis, asthma, malabsorptive syndromes, hypertension, hyperlipidaemia, ischaemic heart disease, stroke, myocardial infarction, congestive heart failure, malignancy, chronic obstructive pulmonary disease, kidney failure, cerebrovascular disease, peripheral vascular disease, dementia, neoplasm, diabetes, ulcers, hemiplegia, renal disease, inflammatory bowel disease, use of Proton pump inhibitors, antiarrhythmics, anticonvulsants, antidepressants, anti-Parkinson drugs, thiazide diuretics, anxiolytics, platelet inhibitors, warfarin, angiotensin-converting enzyme inhibitors, beta blockers, calcium channel blockers, loop diuretics, nonstatin lipid lowering drugs, corticosteroids, insulin, oral antidiabetic drugs, nonsteroidal anti-inflammatory drugs, hormone replacement therapy, bisphosphonates, selective oestrogen receptor modulators

² Propensity score based on a logistic regression model to predict statin exposure. All variables included in the fully adjusted model were used to calculate the propensity score

³ Sub-analysis of hips is based on 78,594 participants, with 2,071 revisions

⁴ Sub-analysis of knees is based on 72,711 participants, with 1,429 revisions